2-Hydroxybenzylamine

2-HOBA (2-hydroxybenzylamine, salicylamine) is a small-molecule scavenger that mops up isolevuglandins (isoLGs), reactive byproducts of lipid peroxidation that damage HDL and other proteins. Vanderbilt is running a Phase 2 trial in heterozygous familial hypercholesterolemia (NCT04941599, n=72) testing whether 2-HOBA improves HDL cholesterol efflux capacity [1]. The asset has no pharma sponsor, no FDA designations, and a multi-indication academic Phase 2 portfolio (lupus, RA, atrial fibrillation, Long COVID POTS) [2][3][4][5]. The first completed human efficacy readout - a post-ablation atrial fibrillation pilot - was negative: 2-HOBA significantly increased AF recurrence vs placebo (OR 3.65, 95% CI 1.31-10.16, p=0.013) [6]. That result materially weakens the broader mechanistic bet.

First-in-class novel compound, never approved anywhere, distinct from the older topical antimicrobials that share the salicylamine ingredient name. Phase 1 safety and pharmacokinetics were published by Pitchford et al. in 2019 (single dose) and 2020 (repeat dose), both showing acceptable tolerability in healthy volunteers [7][8]. Dosing across the Phase 2 program is consistent: 750 mg orally three times daily (TID) [3][6]. Phase 2 portfolio: FH/HDL (NCT04941599, recruiting) [1]; lupus blood pressure (NCT07225543, recruiting) [2]; Long COVID POTS (NCT07189936, recruiting) [4]; rheumatoid arthritis (NCT05274243, n=32, primary completion May 28 2025, results not yet posted to ClinicalTrials.gov as of mid-2026) [5]; and the completed atrial fibrillation post-ablation pilot (Yoneda et al. 2025) [6]. Zero FDA designations: no breakthrough, fast track, orphan, accelerated approval, or priority review. Sponsor on every trial is Vanderbilt University Medical Center. No public timeline for the FH readout - estimated 2026-2027 based on enrollment status. The asset has been in Phase 2 territory for years without attracting a pharma partner, which itself is a status signal.

When fats get oxidized in the body - under inflammation, hypertension, hyperlipidemia - they generate gamma-ketoaldehydes called isolevuglandins (isoLGs). These molecules are chemically aggressive: they latch onto lysine residues (the amine-bearing side chains of the lysine amino acid building blocks of proteins) and lock those proteins up, including HDL. Damaged HDL stops doing its day job, which is dragging cholesterol back out of arteries (reverse cholesterol transport). 2-HOBA is bait. Its primary amine group is positioned next to an ortho-hydroxyl that stabilizes the initial Schiff-base/hemiketal adduct with the isoLG dicarbonyl, making the trapping reaction roughly two orders of magnitude faster than the analogous reaction with protein lysines. The 'chemical sponge' analogy: 2-HOBA soaks up the corrosive species before they stick to anything important. The mechanism is well-characterized at the bench and supported by Vanderbilt preclinical work - 2-HOBA reduced atherosclerosis ~60% in hypercholesterolemic Ldlr−/− mice without lowering plasma cholesterol [9], and blunted angiotensin-II-driven hypertension via reduced isoLG-adducted dendritic cell antigens [10]. Because isoLGs form wherever oxidative stress drives lipid peroxidation, the same mechanism plausibly connects to the inflammation-driven pathology in lupus, rheumatoid arthritis, and the atrial-tissue oxidative stress implicated in AF - that is the scientific rationale for the multi-indication spread. The honest gap: nobody has yet shown in humans that lowering isoLG-adduct burden translates into clinical benefit, and the first completed human efficacy pilot (AF post-ablation) trended the wrong way [6].

NCT04941599 is a Phase 2 trial in heterozygous FH, target n=72, randomized against placebo, primary endpoint is HDL cholesterol efflux capacity - a functional assay measuring how well a patient's HDL pulls cholesterol out of macrophages (the cholesterol-laden immune cells inside artery walls that drive plaque) [1]. This is a surrogate, not a clinical outcome. Even a clean win on efflux capacity does not establish that 2-HOBA reduces heart attacks or strokes in FH patients. The choice fits an academic mechanistic Phase 2: prove the biology works in humans, then chase a sponsor for an outcomes trial. Enrollment is single-site Vanderbilt; FH is a defined population with established registries so recruitment is feasible but slow. The atrial fibrillation pilot (Yoneda et al. Circ Arrhythm Electrophysiol 2025, NCT04433091, n=23 randomized 1:1 to 2-HOBA 750 mg TID or placebo starting 3 days pre-ablation, smartwatch-monitored 28 days post-ablation) is the most informative completed dataset and reported the opposite of the hoped-for direction: 2-HOBA significantly increased AF recurrence (adjusted OR 3.65, 95% CI 1.31-10.16, p=0.013), with no safety signal that would account for it [6]. The completed rheumatoid arthritis trial (NCT05274243, n=32, 750 mg TID × 4 weeks, primary completion May 2025) had safety/tolerability and isoLG-adduct change as primary endpoints; results have not been posted to ClinicalTrials.gov nor published as of mid-2026 [5]. The pattern across the portfolio is consistent: small Phase 2 mechanism trials, no Phase 3 visible, and now one negative efficacy readout in the books.

The model gives this drug a 4% chance of eventually reaching approval. That starts from a historical baseline - about 27% of drugs in this area that enter Phase 2 ultimately get approved - then shifts based on ten specific facts about the trial and the sponsor. The biggest drags on the estimate are an unusually complex blinding design, the sponsor's thin approval track record, and weaker-than-typical earlier-phase results. The remaining factors fall close to average for this stage, so they leave the estimate roughly where the baseline set it.

Efficacy risk is the dominant one and has gotten worse. The AF post-ablation pilot reported 2-HOBA significantly increased AF recurrence vs placebo [6] - the first human efficacy test of the isoLG-scavenging mechanism, in the wrong direction. That does not rule out benefit in FH or autoimmune indications, but it removes the easy 'biology travels' read. HDL efflux capacity remains mechanistically appealing but has a graveyard of correlates that did not translate: CETP inhibitors (cholesteryl ester transfer protein blockers - they pharmacologically raise HDL but failed to reduce heart attacks in REVEAL, ILLUMINATE, dal-OUTCOMES, and ACCELERATE) and niacin all moved HDL without delivering outcomes. A positive efflux readout buys mechanism, not approval. Safety risk: cumulative published exposure is still roughly 50 healthy volunteers from Phase 1 [7][8] plus the small AF cohort with no reported safety signal [6]; rare adverse events remain unknown. Execution risk: every active trial is Vanderbilt-sponsored, single-site or small, with no commercial development infrastructure behind it. Commercial risk is the most punishing. 2-HOBA is a simple small molecule and the available patent literature is dominated by method-of-use filings (e.g., WO2018009875A1, 'Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers,' Vanderbilt, PCT filing 2017, expected expiry ~2037) [11] rather than strong composition-of-matter coverage on 2-HOBA itself, which is a known compound in the buckwheat literature. We did not find a Vanderbilt composition-of-matter patent specifically claiming 2-HOBA as a novel chemical entity; absence of such a patent is itself the finding and a meaningful exclusivity risk. No pharma partner, no obvious payer willingness for an add-on therapy to statins without outcomes data. Even an unambiguous Phase 2 win likely needs a deep-pocketed sponsor to fund an outcomes trial in FH, and none has stepped up yet.

Worth tracking, low priority - and the AF pilot result lowers it further. The real signal is not the FH Phase 2 readout itself - it is whether anyone with capital picks it up afterward. Watch for: (1) a pharma licensing or partnership announcement from Vanderbilt's tech transfer office, (2) HDL efflux capacity improvement with concurrent reduction in isoLG-protein adducts in the FH trial - both moving together is the mechanistic gold standard, (3) any FDA designation, which would suggest someone is preparing for a registrational path, and (4) results posting for the completed RA trial (NCT05274243) [5], which will tell us whether isoLG-adduct burden actually drops in an inflammatory disease and whether the safety profile holds in a patient population. Without item 1, this stays an academic program no matter how clean the biology looks. Check back when the FH trial posts results on ClinicalTrials.gov, estimated 2026-2027. The multi-indication Phase 2 spread (FH, lupus, RA, AF, LC-POTS - Postural Orthostatic Tachycardia Syndrome, a dysautonomia causing rapid heart rate on standing that has become a defining sequela in Long COVID) is the classic academic strategy of finding which disease shows the strongest signal; it can work but rarely produces a pharma-ready asset without external capital, and one negative human pilot already makes the next sponsor conversation harder. Vanderbilt is the only entity carrying it. That fact, more than any biology, is the binding constraint.